TITLE

Desirudin: A Review of its Use in the Management of Thrombotic Disorders

AUTHOR(S)
Matheson, A.J.; Goa, K.L.
PUB. DATE
September 2000
SOURCE
Drugs;Sep2000, Vol. 60 Issue 3, p679
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Desirudin, a recombinant hirudin used in the prevention and management of thromboembolic disease, is a thrombin inhibitor which binds directly and with high affinity to clot-bound and fluid phase thrombin. As a prophylaxis in patients undergoing hip replacement surgery, desirudin was significantly more effective in reducing the incidence of deep vein thrombosis (DVT) than either unfractionated or low molecular weight heparin. However, results in patients with acute coronary syndromes are less conclusive. A significant reduction with desirudin compared with heparin in the incidence of death or non-fatal (re)infarction at 24 hours in patients with acute myocardial infarction (MI) was reported in the GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) IIb trial but not in the TIMI (Thrombolysis and Thrombin Inhibition in Myocardial Infarction) 9B trial. Despite the early reduction shown in GUSTO IIb, desirudin was not associated with an improved long term clinical benefit at 30 days compared with heparin. Similar results were seen in patients with unstable angina/non-Q-wave MI enrolled in the GUSTO IIb trial. In addition, desirudin and heparin showed similar efficacy in preventing restenosis 30 weeks after coronary angioplasty for unstable angina, despite desirudin being associated with a significant reduction in the rate of cardiac events within the first 96 hours. Desirudin is as well tolerated as heparin with a similar incidence of moderate and severe bleeding, intracranial haemorrhage or stroke reported when trialled in the prevention of DVT associated with hip replacement surgery or the treatment of acute coronary syndromes. However, in the GUSTO IIb trial a significantly higher incidence of transfusions was observed in patients with unstable angina/ non-Q-wave MI. Conclusions: Desirudin is clearly more effective than heparin in the prevention of DVT in patients undergoing elective hip replacement, although cost factors may influence its ultimate place in therapy. In the treatment of acute coronary syndromes the role of desirudin is less certain; however, it may be useful for patients in whom heparin therapy is not a viable option.
ACCESSION #
9593386

 

Related Articles

  • Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Angelillo-Scherrer, Anne; de Frutos, Pablo Garcia; Aparicio, Cristina; Melis, Els; Savi, Pierre; Lupu, Florea; Arnout, Jef; Dewerchin, Mieke; Hoylaerts, Marc F.; Herbert, Jean-Marc; Collen, Desire; Dahlback, Bjorn; Carmeliet, Peter // Nature Medicine;Feb2001, Vol. 7 Issue 2, p215 

    The growth arrest-specific gene 6 product (Gas6) is a secreted protein related to the anticoagulant protein S but its role in hemostasis is unknown. Here we show that inactivation of the Gas6 gene prevented venous and arterial thrombosis in mice, and protected against fatal...

  • Diagnosis of deep vein thrombosis using autologous indium-III-labelled platelets. Fenech, Albert; Hussey, J.K.; Smith, F.W.; Dendy, P.P.; Bennett, B.; Douglas, A.S. // British Medical Journal (Clinical Research Edition);3/28/1981, Vol. 282 Issue 6269, p1020 

    Investigates the diagnosis of deep vein thrombosis using autologous indium-III-labelled platelets. Performance of imaging with a gamma-camera linked with data display facilities; Accumulation of indium-III at sites; Effectiveness of radioisotopic technique.

  • Platelets in atherothrombosis. Ruggeri, Zaverio M. // Nature Medicine;Nov2002, Vol. 8 Issue 11, p1227 

    Discusses the participation of platelets in atherothrombosis. Platelet adhesion; Platelet activation and procoagulant activity; Effects of blood flow on platelet adhesion and aggregation.

  • Role of thrombin signalling in platelets in haemostasis and thrombosis. Sambrano, Gilberto R.; Weiss, Ethan J.; Yao-Wu Zheng; Wei Huang; Coughlin, Shaun R. // Nature;9/6/2001, Vol. 413 Issue 6851, p74 

    Discusses the influence of thrombin signalling in platelet function during periods of hemostasis and thrombosis. Cellular response triggered by thrombin; Failure to change shape in thrombins.

  • Gap junctions used by platelets for communication.  // British Journal of Hospital Medicine (17508460);May2012, Vol. 73 Issue 5, p249 

    The article reports a study which reveled that gap junctions, platelets use specialized pore-like structures, for direct communication between the cells and with the inner walls of blood vessels, which may help develop more effective anti-thrombotic therapies against heart attacks and strokes.

  • CATS: High platelet count predicted VTE in patients with cancer.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p30 

    The article focuses on the Vienna Cancer and Thrombosis Study that found that a high platelet count was associated with a threefold or more increased risk for venous thromboembolism.

  • Thrombocytopenia.  // Encyclopedic Reference of Molecular Pharmacology;2004, p908 

    A definition of the term "thrombocytopenia" is presented. It refers to a decrease in the number of circulating blood platelets. Although severe thrombocytopenia can lead to spontaneous bleeding, a few disorders, such as heparin-induced thrombocytopenia, are paradoxically associated with an...

  • Discovery of Potent Peptide-Mimetic Antagonists for the Human Thrombin Receptor, Protease-Activated Receptor-1 (PAR-1). Maryanoff, B.E.; Zhang, H-C.; Andrade-Gordon, P.; Derian, C.K. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Mar2003, Vol. 1 Issue 1, p13 

    Protease-activated receptors (PARs) represent a unique family of seven-transmembrane G-protein-coupled receptors, which are enzymatically cleaved to expose a new extracellular N-terminus that acts as a tethered activating ligand. PAR-1 is cleaved and activated by the serine protease a-thrombin,...

  • Development of Peptide Inhibitors to Block Type I and Type III Collagen-platelet Interaction. Chiang, T.M. // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jun2003, Vol. 1 Issue 2, p171 

    Platelet-collagen interaction plays an important role in hemostasis and pathological thrombosis. Upon an injury to the subendothelium of a blood vessel wall, platelets attach to the denuded substrate, aggregate, and release biological substances. Many investigators are trying to explore blocking...

  • Morphine-Potentiated Platelet Aggregation in in vitro and Platelet Plug Formation in in vivo Experiments. Hsiao, George; Ming-Yi Shen; Chiao-Ling Fang; Duen-Suey Chou; Chien-Huang Lin; Tzeng-Fu Chen; Joen-Rong Sheu // Journal of Biomedical Science;May/Jun2003, Vol. 10 Issue 3, p292 

    The detailed mechanisms underlying morphine-signaling pathways in platelets remain obscure. Therefore, we systematically examined the influence of morphine on washed human platelets. In this study, washed human platelet suspensions were used for in vitro studies. Furthermore, platelet thrombus...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics